Pfizer
BSE: 500680 | NSE: PFIZER | ISIN: INE182A01018 | Pharmaceuticals
 |
Profit & Loss account of Pfizer |
------------------- in Rs. Cr. ------------------- |
| Nov '04 | Nov '05 | Nov '06 | Nov '07 | Nov '08 | ||||||
|
||||||||||
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||||||
|
||||||||||
| Income | ||||||||||
| Sales Turnover | 684.83 | 724.15 | 791.98 | 794.27 | 786.74 | |||||
| Excise Duty | 48.84 | 63.27 | 63.02 | 62.97 | 57.72 | |||||
| Net Sales | 635.99 | 660.88 | 728.96 | 731.30 | 729.02 | |||||
| Other Income | -14.70 | -18.95 | 3.33 | 294.55 | 264.86 | |||||
| Stock Adjustments | -23.12 | 34.09 | 10.27 | -4.69 | 22.97 | |||||
| Total Income | 598.17 | 676.02 | 742.56 | 1,021.16 | 1,016.85 | |||||
| Expenditure | ||||||||||
| Raw Materials | 201.63 | 240.63 | 236.01 | 228.50 | 262.07 | |||||
| Power & Fuel Cost | 8.02 | 7.96 | 7.22 | 7.94 | 7.17 | |||||
| Employee Cost | 82.48 | 100.14 | 102.34 | 101.70 | 102.10 | |||||
| Other Manufacturing Expenses | 22.46 | 29.83 | 29.90 | 29.05 | 30.99 | |||||
| Selling and Admin Expenses | 163.79 | 147.08 | 162.35 | 168.87 | 162.81 | |||||
| Miscellaneous Expenses | 25.19 | 20.51 | 22.88 | 19.05 | 17.26 | |||||
| Preoperative Exp Capitalised | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Total Expenses | 503.57 | 546.15 | 560.70 | 555.11 | 582.40 | |||||
| Nov '04 | Nov '05 | Nov '06 | Nov '07 | Nov '08 | ||||||
|
||||||||||
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||||||
|
||||||||||
| Operating Profit | 109.30 | 148.82 | 178.53 | 171.50 | 169.59 | |||||
| PBDIT | 94.60 | 129.87 | 181.86 | 466.05 | 434.45 | |||||
| Interest | 0.81 | 0.16 | 0.07 | 0.02 | 0.00 | |||||
| PBDT | 93.79 | 129.71 | 181.79 | 466.03 | 434.45 | |||||
| Depreciation | 10.26 | 13.85 | 13.07 | 9.58 | 11.12 | |||||
| Other Written Off | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Profit Before Tax | 83.53 | 115.86 | 168.72 | 456.45 | 423.33 | |||||
| Extra-ordinary items | 0.27 | -0.28 | 0.00 | 1.60 | 4.30 | |||||
| PBT (Post Extra-ord Items) | 83.80 | 115.58 | 168.72 | 458.05 | 427.63 | |||||
| Tax | 29.32 | 41.13 | 56.28 | 111.20 | 119.44 | |||||
| Reported Net Profit | 45.52 | 68.12 | 105.73 | 338.93 | 299.12 | |||||
| Total Value Addition | 301.93 | 305.51 | 324.69 | 326.62 | 320.32 | |||||
| Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Equity Dividend | 29.84 | 29.84 | 37.30 | 82.06 | 37.30 | |||||
| Corporate Dividend Tax | 3.90 | 4.19 | 5.23 | 13.95 | 6.34 | |||||
| Per share data (annualised) | ||||||||||
| Shares in issue (lakhs) | 287.98 | 298.41 | 298.41 | 298.41 | 298.41 | |||||
| Earning Per Share (Rs) | 15.81 | 22.83 | 35.43 | 113.58 | 100.24 | |||||
| Equity Dividend (%) | 100.00 | 100.00 | 125.00 | 275.00 | 125.00 | |||||
| Book Value (Rs) | 118.66 | 126.19 | 147.36 | 217.36 | 301.45 | |||||
| ||||||||||
| Source : Religare Technova | ||||||||||
| Explore Pfizer connections | ||||||||||
| ||||||||||
